The study sought to repurpose ceftriaxone for MYCN‐amplified retinoblastoma (RB) and neuroblastoma (NB) treatment due to its observed capability to reduce MYCN‐driven RB subtype volume. This evidence concerns the gene MYCN and retinoblastoma.